A growing movement, particularly in the US, legally allows patients with terminal diseases to try unapproved therapies. This framework gives patients who have exhausted all other options the right to take a knowing risk on a potentially life-saving treatment.

The field of research ethics, once focused on protecting vulnerable subjects from harm, has evolved. A cultural emphasis on individual liberty, exemplified by the "right-to-try" movement, has created a new ethos where patients demand access to experimental treatments, even with high risks.

The rationale for "virus hunting" is to create advance vaccines. However, you cannot safely test a vaccine for a novel, deadly pathogen on healthy humans. This makes the knowledge unactionable for prevention, while creating immense risk by bringing dangerous pathogens into leaky labs and publicizing their existence.

The FDA's conflict with Unicure over its Huntington's gene therapy highlights a significant philosophical shift. New leadership is demanding rigorous sham-controlled trials, involving drilling into patients' skulls for a placebo, a stark contrast to the previous, more flexible regime. This signals a much higher, potentially prohibitive, evidence bar for future gene therapies.

The scientific gold standard of a placebo-controlled trial creates a profound ethical burden for researchers in neonatal care. To prove a drug's efficacy for widespread use, scientists must knowingly deny the potentially life-saving treatment to half of the fragile infants in a study, forcing them to carry the pain of that decision.

For uniQure's Huntington's therapy, the FDA demands a placebo-controlled trial requiring patients to undergo a 14-18 hour sham brain surgery—a procedure European regulators deemed unethical. This creates a major barrier to proving the drug's efficacy for a fatal disease.

The typical path for a new, high-risk biology is to test it in patients with no other options, like in oncology. The COVID-19 pandemic forced a massive deviation from this norm. For the first time, a completely new class of medicine (mRNA) was deployed at scale in healthy individuals, not the sickest.

As AI models become adept at identifying novel or experimental treatments for individuals, it will create mounting pressure on the medical regulatory system. Patients, armed with compelling, AI-generated arguments for a specific therapy, will increasingly challenge the gates kept by establishments, potentially forcing an evolution of the social contract around access to unproven medicines ('right to try').

The traditional medical ethos prevents interventions on non-sick patients. This conservative approach may be irrational when low-risk therapies could add decades of healthy life, challenging the fundamental definition of when a doctor should act.